Codexis, Inc.
NASDAQ:CDXSBiotechnology
Healthcare
$1.15 +0.60%
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
52W Low $0.96High $3.87
Volume 1.47M
Average 1.15M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$19.38M
FY 2025 · Annual
Investing Cash Flow
$23.50M
FY 2025 · Annual
Financing Cash Flow
$27.93M
FY 2025 · Annual
-53.9% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Depreciation & Amortization | 5.95M | 10.25M | 9.92M | 4.95M | 5.25M |
| Deferred Income Tax | (2.89M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.59M | 14.53M | 9.97M | 13.09M | 9.62M |
| Change in Working Capital | (7.62M) | 21.57M | (18.22M) | (12.02M) | 6.42M |
| Accounts Receivables | (15.57M) | (3.23M) | 20.25M | 1.25M | 8.51M |
| Inventory | (196K) | (869K) | (656K) | 886K | (19K) |
| Accounts Payables | 268K | 207K | 2.29M | (2.57M) | (1.29M) |
| Other Working Capital | 7.88M | 25.46M | (40.1M) | (11.59M) | (784K) |
| Other Non-Cash Items | (19K) | (1.48M) | 21.93M | 9.85M | 3.31M |
| Operating Cash Flow | (14.27M) | 11.28M | (52.64M) | (49.41M) | (19.38M) |
| Capital Expenditures | (13.83M) | (8.31M) | (4.42M) | (4.31M) | (4.47M) |
| Acquisitions (Net) | 36K | 29K | 751K | 87K | 5K |
| Purchases of Investments | (7.63M) | (5.3M) | (1.19M) | (90.24M) | (57.16M) |
| Sales of Investments | (36K) | (29K) | 440K | 37.47M | 85.13M |
| Other Investing Activities | 36K | 29K | (440K) | 0 | 0 |
| Investing Cash Flow | (21.42M) | (13.58M) | (4.86M) | (56.98M) | 23.5M |
| Debt Repayment | 0 | 0 | 0 | 29.52M | 9.89M |
| Common Stock Issued | 4.97M | 913K | 8.65M | 31.32M | 18.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.21M) | (1.49M) | (485K) | (318K) | 0 |
| Financing Cash Flow | 3.77M | (575K) | 8.17M | 60.52M | 27.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (31.92M) | (2.87M) | (49.33M) | (45.87M) | 32.05M |
| Free Cash Flow | (28.1M) | 2.98M | (57.06M) | (53.72M) | (23.85M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$44.0M
+ D&A$5.2M
+ Stock-Based Comp$9.6M
+ Deferred Tax$0
+ Working Capital$6.4M
+ Other Non-Cash$3.3M
= Operating Cash Flow-$19.4M
- Capex-$4.5M
= Free Cash Flow-$23.8M
Analysis
FY2025 free cash flow is -$23.8M. FCF conversion is 54.2% of net income. Operating cash flow was -$19.4M, with capex of -$4.5M. The largest bridge item is Stock-Based Comp at $9.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 |
Does CDXS generate free cash flow?
Codexis, Inc. (CDXS) generated -$23.85M of free cash flow in fiscal 2025.
How much operating cash flow does CDXS produce?
Operating cash flow was -$19.38M, before capital expenditures of $4.47M.
Continue the stock analysis
Jump to another research area for this company.